![ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”](https://cdn.cancerletter.com/media/2023/09/29153054/49-36-4x3-1.jpg)
![ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”](https://cdn.cancerletter.com/media/2023/09/29153054/49-36-4x3-1.jpg)
Cover Story
Clinical
If you’ve been following the saga of drug shortages in this publication, you know how America’s cancer institutions are scrambling to obtain platinum-based drugs for their patients.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities
- Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.” - A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital